Hutchmed China hails lung cancer trial results published in Lancet
(Alliance News) - Hutchmed China Ltd on Wednesday said the results from its SACHI phase-three lung cancer trial have been published in medical journal the Lancet. Read More
| Price | 239.00p on 16-01-2026 at 18:50:07 |
|---|---|
| Change | 13.00p 5.75% |
| Buy | 239.00p |
| Sell | 236.00p |
| Last Trade: | Sell 1,495.00 at 239.00p |
| Day's Volume: | 141,476 |
| Last Close: | 239.00p |
| Open: | 231.00p |
| ISIN: | KYG4672N1198 |
| Day's Range | 230.00p - 239.00p |
| 52wk Range: | 187.50p - 292.00p |
| Market Capitalisation: | £2.05b |
| VWAP: | 232.87132p |
| Shares in Issue: | 859.52m |
Sector: Medicine and Biotech
Listed In: FTSE AIM 100, FTSE AIM All-Share,
Hutchmed (HCM) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Sell* | 1,495 | 239.00p | Uncrossing Trade |
16:35:26 - 16-Jan-26 |
| Sell* | 100 | 236.00p | Ordinary |
16:28:04 - 16-Jan-26 |
| Sell* | 224 | 235.12p | Ordinary |
16:24:33 - 16-Jan-26 |
| Sell* | 700 | 234.15p | Ordinary |
16:09:40 - 16-Jan-26 |
| Buy* | 5 | 239.00p | SI Trade |
16:08:17 - 16-Jan-26 |
| Buy* | 1 | 239.00p | Automatic Execution |
16:08:17 - 16-Jan-26 |
| Sell* | 1 | 234.10p | Ordinary |
15:55:20 - 16-Jan-26 |
| Buy* | 291 | 235.00p | Automatic Execution |
15:32:19 - 16-Jan-26 |
| Buy* | 2,850 | 235.00p | Automatic Execution |
15:32:19 - 16-Jan-26 |
| Buy* | 2,150 | 235.00p | Automatic Execution |
15:32:19 - 16-Jan-26 |
Hutchmed (HCM) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 14th Jan 2026 7:00 am | RNS-R | Publication of Phase III Results in The Lancet |
| 7th Jan 2026 7:00 am | RNS-R | Positive Topline Results of Phase III Trial |
| 5th Jan 2026 7:00 am | RNS-R | Surufatinib + Camrelizumab PDAC Phase 3 initiation |
| 31st Dec 2025 7:00 am | RNS | Total Voting Rights |
| 31st Dec 2025 7:00 am | RNS | Total Voting Rights |
| 30th Dec 2025 10:00 am | RNS-R | China NDA Acceptance-Savolitinib in Gastric Cancer |
| 30th Dec 2025 10:00 am | RNS-R | China NDA Acceptance-Savolitinib in Gastric Cancer |
| 29th Dec 2025 8:30 am | RNS | Blocklisting Six Monthly Return |
| 29th Dec 2025 8:30 am | RNS-R | NDA Acceptance in China for Fanregratinib |
| 29th Dec 2025 8:30 am | RNS-R | NDA Acceptance in China for Fanregratinib |